Drug Trial Radar · NCT03402659
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Oct 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Dec 29, 2017
Primary completion
Jun 30, 2019
Study completion Jul 31, 2019
Sponsor
- Lead sponsor
- EIP Pharma IncIndustry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials; Amsterdam UMC, location VUmc
- First posted
- Jan 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate significant improvement relative to placebo-treatment in episodic memory function, as assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.
Conditions
- Alzheimer Disease
Interventions
neflamapimodDrug
40 mg neflamapimod capsule
placeboOther
matching placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R)Time frame: Baseline and 24 weeks
Locations
38 sites in 5 countries. Site status is shown where the registry gives one.
Alliance for Research
Long Beach, California
Pacific Research Network
San Diego, California
CITrials
Santa Ana, California
Southern California Research, LLC
Simi Valley, California
Viking Clinical Research
Temecula, California
Miami Dade Medical Research Institute
Miami, Florida
Sensible Healthcare, LLC
Ocoee, Florida
Anchor Neuroscience
Pensacola, Florida
Progressive Medical Research
Port Orange, Florida
Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida
Florida Premier Research Institute
Winter Park, Florida
Northwest Clinical Trials
Boise, Idaho
MassGeneral Institute for Neurodegenerative Disease
Charlestown, Massachusetts
Manhattan Behavioral Medicine
New York, New York
Alzheimer's Memory Center and Research Institute
Charlotte, North Carolina
Northwest Clinical Research Center
Seattle, Washington
Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s.
Choceň, Czechia
Cerebrovaskulární poradna s.r.o.
Moravská Ostrava, Czechia
Clintrial S.R.O
Prague, Czechia
Private Psychiatric Centre
Prague, Czechia
Vestra Clinics S.R.O
Rychnov nad Kněžnou, Czechia
CCBR Clinical Research, Aalborg
Aalborg, Denmark
CCBR Clinical Research, Ballerup
Ballerup Municipality, Denmark
CCBR Clinical Research, Vejle
Vejle, Denmark
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
Alzheimer Research Center
Amsterdam, Netherlands
Amphia Ziekhuis
Breda, Netherlands
MAC Clinical Research Tankersley
Barnsley, United Kingdom
Re:Cognition Health Birmingham
Birmingham, United Kingdom
MAC Clinical Research Blackpool
Blackpool, United Kingdom
Fulbourn Hospital
Cambridge, United Kingdom
MAC Clinical Research Leeds
Leeds, United Kingdom
MAC Clinical Research Liverpool
Liverpool, United Kingdom
Re:Cognition Health London
London, United Kingdom
St. Pancras Clinical Research
London, United Kingdom
MAC Clinical Research Manchester
Manchester, United Kingdom
Re:Cognition Health Plymouth
Plymouth, United Kingdom
5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust
Warrington, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.